Brought to you by 
Seres Health closes $10.6mm B round
02 Dec 2014
Executive Summary
Seres Health Inc. (developing Ecobiotic therapeutics for various diseases by targeting the underlying biology of the microbiome) raised $10.6mm in its Series B round to returning shareholders Flagship Ventures and Enso Ventures, and first-time backers Mayo Clinic (which also concurrently entered into a drug discovery and development partnership with the company), Alexandria Venture Investments, and six private investors. Funds will support development of Seres' pipeline, which includes lead candidate SER109 (Phase I) for C. difficile.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Seres Health closes $10.6mm B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice